Novel Combination Therapy Reduces Endometrial Cancer Recurrence and Mortality

Initial data from the TroFuse-005/ENGOT-en23/GOG-3095 study, presented at ESMO and published in The Lancet, indicates a novel drug combination for endometrial cancer has shown promise. The findings demonstrate a reduction in both recurrence and death for patients, offering a hopeful development for a disease with rising incidence and mortality rates.